These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 6183045)

  • 41. Insulin antibody production studied quantitatively with a modified radioimmunoassay technique and with radioimmunoelectrophoresis in patients treated with monocomponent (MC) insulin.
    Bruni B; Ricci C; Giolitti A; Osenda M; D'Alberto M; Turco GL
    J Nucl Biol Med; 1973; 17(3):123. PubMed ID: 4746315
    [No Abstract]   [Full Text] [Related]  

  • 42. [Allergy to insulin].
    García-Ortega MP
    Med Clin (Barc); 1985 Apr; 84(13):535-7. PubMed ID: 3889517
    [No Abstract]   [Full Text] [Related]  

  • 43. [Insulin resistance: etiology, pathogenesis and therapeutic possibilities].
    Koivisto V
    Duodecim; 1981; 97(12):825-36. PubMed ID: 7297450
    [No Abstract]   [Full Text] [Related]  

  • 44. Diagnostic algorithm and management of immune-mediated complications associated with subcutaneous insulin therapy.
    Jaeger C; Eckhard M; Brendel MD; Bretzel RG
    Exp Clin Endocrinol Diabetes; 2004 Sep; 112(8):416-21. PubMed ID: 15372360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [On the therapy of insulin resistance].
    Fankhauser S
    Praxis; 1969 Sep; 58(35):1082-7. PubMed ID: 5820310
    [No Abstract]   [Full Text] [Related]  

  • 46. [Insulin therapy today].
    Willms B
    Internist (Berl); 1981 Apr; 22(4):211-8. PubMed ID: 7014510
    [No Abstract]   [Full Text] [Related]  

  • 47. IgG heavy-chain (Gm) allotypes and immune response to insulin in insulin-requiring diabetes mellitus.
    Nakao Y; Matsumoto H; Miyazaki T; Mizuno N; Arima N; Wakisaka A; Okimoto K; Akazawa Y; Tsuji K; Fujita T
    N Engl J Med; 1981 Feb; 304(7):407-9. PubMed ID: 6779158
    [No Abstract]   [Full Text] [Related]  

  • 48. Exogenous insulin needs. Relationship with duration of diabetes, C-peptidemia, insulin antibodies, and retinopathy.
    Haumont D; Dorchy H; Toussaint D; Despontin M
    Helv Paediatr Acta; 1982 May; 37(2):143-50. PubMed ID: 7047466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Insulin resistance due to antibody in type I diabetes].
    Enríquez Acosta L
    Rev Clin Esp; 1984 Jan; 172(1):57-8. PubMed ID: 6369446
    [No Abstract]   [Full Text] [Related]  

  • 50. Selective IgG subclass antibody response to insulin in diabetic patients receiving animal insulin replacement therapy.
    Siddiqi MA; Wangnoo SK
    Int Arch Allergy Appl Immunol; 1989; 89(1):49-53. PubMed ID: 2659538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Different insulin antibody formation in diabetic patients treated with crystallized or highly purified insulins is a transient phenomenon.
    Keilacker H; Rjasanowski I; Woltanski KP; Kohnert KD; Ziegler M; Michaelis D
    Horm Metab Res; 1989 Jul; 21(7):398-9. PubMed ID: 2777200
    [No Abstract]   [Full Text] [Related]  

  • 52. New insulins: their role in the treatment of diabetes.
    Caterson I
    Drugs; 1979 Apr; 17(4):289-96. PubMed ID: 456293
    [No Abstract]   [Full Text] [Related]  

  • 53. Insulin antibody formation during long-term treatment with monocomponent and monospecies insulin.
    Piers DA; Sluiter WJ; Reitsma WD; Doorenbos H
    Neth J Med; 1974; 17(4-5):234-8. PubMed ID: 4465730
    [No Abstract]   [Full Text] [Related]  

  • 54. [Clinical problems of antibody formation in insulin therapy].
    Nakagawa M
    Horumon To Rinsho; 1972 May; 20(5):353-6. PubMed ID: 4560269
    [No Abstract]   [Full Text] [Related]  

  • 55. [Determination of insulin antibody and its significance--with special reference to insulin antibody determination by the antibody binding method and the complement consumption method and fluorescent antibody technic].
    Onoe K; Kobashi K; Fujinaka S
    Nihon Rinsho; 1966 Apr; 24(4):753-68. PubMed ID: 5338258
    [No Abstract]   [Full Text] [Related]  

  • 56. Measurement of immune complexes in insulin-treated diabetics.
    Jayarao KS; Faulk WP; Karam JH; Grodsky GM; Forsham PH
    J Immunol Methods; 1973 Dec; 3(4):337-45. PubMed ID: 4591347
    [No Abstract]   [Full Text] [Related]  

  • 57. Insulin-binding antibody and hormone dosage in non-resistant diabetes.
    Hurn BA; Farrant PC; Young BA; Grahame A
    Postgrad Med J; 1969 Dec; ():Suppl:819+. PubMed ID: 5393006
    [No Abstract]   [Full Text] [Related]  

  • 58. [New prospects of insulin therapy. Review].
    Bruni B
    Minerva Med; 1971 Jun; 62(48):2431-40. PubMed ID: 4932241
    [No Abstract]   [Full Text] [Related]  

  • 59. [Insulin antibodies in untreated and insulin-treated diabetics].
    Ditsov S; Penchev I; Andreev D; Sirakov L; Turkolev N
    Vutr Boles; 1972; 11(3):95-9. PubMed ID: 4679989
    [No Abstract]   [Full Text] [Related]  

  • 60. Insulin allergy.
    Joshi SR; Shah SN
    J Assoc Physicians India; 1997; Suppl 1():37-40. PubMed ID: 11235633
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.